Sage Journals: Discover world-class research

Abstract

PURPOSE:

MicroRNAs (miRNAs) have been reported to be involved in tumorigenesis. The aim of this study was to investigate the functional role and prognostic value of miR-652 in gastric cancer (GC).

METHODS:

Quantitative real-time polymerase chain reaction (qRT-PCR) was used to determine the expression levels of miR-652 in human GC tissue samples and GC cell lines. The Kaplan-Meier survival curves and Cox regression analysis were performed to measure the prognostic value of miR-652 in GC. The tumor cell proliferation capacity was estimated by MTT assay, and cell migration and invasion were assessed by Transwell assays. The luciferase reporter assay was performed to confirm the target gene of miR-652.

RESULTS:

MiR-652 was significantly elevated in GC tissues and cell lines (all $P<$ 0.001). And the expression level of miR-652 was significantly associated with TNM stage and lymph node metastasis (all $P<$ 0.05). GC patients with high expression of miR-652 had a shorter overall survival rate than those with low miR-652 expression (log-rank $P<$ 0.001). The miR-652 and TNM stage were proven to be independent prognostic predictors for the GC patients. Overexpressing miR-652 could enhance cell proliferation, migration and invasion (all $P<$ 0.01). RORA was proved to be the target gene of miR-652.

CONCLUSION:

MiR-652 functions as an oncogene in GC and promotes tumor progression via targeting RORA. MiR-652 might be a novel predictive marker for the poor prognosis of GC patients.

Keywords

MicroRNA-652 prognosis progression gastric cancer

1. Introduction

Gastric cancer (GC) is regarded to be one of the most common human cancer, originating from the mucosal epithelium of the stomach [1]. In China, GC affects the quality of patients’ life severely, with high rate of morbidity and mortality [2]. Recently, the number of young patients suffering from GC has a rising tendency [3]. Although the overall incidence of GC declines during the past decades, it remains one of the most common types of cancer and the major causes of cancer-related deaths worldwide [4]. A great progress in the clinical treatment of GC has been made in recent years, but the overall prognosis is always discouraging as a result of postoperative recurrence and metastasis [5]. Thus, researches to investigate the underlying mechanisms of the GC development and metastasis are still of great significance for its clinical treatment [6].

MicroRNAs (miRNAs) is a class of short non-coding RNAs, with the length of approximately 20–24 bases. It can inhibit the translation of the target genes via binding with its 3’-untranslated region (UTR) [7]. An increasing number of miRNAs have been identified to be aberrantly expressed in various types of human cancers, which plays a significant role in tumor formation and progression [8, 9, 10, 11]. In human GC, dysregulation of miRNAs has been reported to be involved in tumor occurrence and development. For instance, Ge et al. found that miR-181a was overexpressed in GC tissues compared to adjacent noncancerous tissues, the upregulation of miR-181a and consequent inhibition of TGF $\beta$ R2 promoted the GC cell migration and proliferation, suggesting miR-181a to be a potential new therapeutic target for GC [12]. Overexpression of miR-371-3p was detected by Guo et al., which can enhance GC cell proliferation, colony formation, migration and invasion, indicating its carcinogenic effect in GC [13]. On the contrary, Zhang et al. proved that the overexpression of miR-133a-3p could block autophagy-mediated glutaminolysis, which in turn suppresses GC progression [14]. Tian et al. reported that the expression level of miR-505 was lower in GC cells, and overexpression of miR-505 inhibited GC cell migration and invasion in vitro by targeting HMGB1 [15]. In addition, the expression level of miR-652 was reported to be upregulated in GC patients than healthy controls, suggesting the potential role in the diagnosis of GC [16]. But the function and prognostic value of miR-652 in GC have not been investigated.

In the present study, we examined the expression of miR-652 in 135 pairs of GC tissues and matched adjacent non-tumorous tissues. Besides, we further investigated its relationship with clinicopathological features and survival of GC patients. Furthermore, cellular functional experiments were also carried out to calculate the effect that miR-652 had on GC behaviors.

2. Materials and methods

2.1 Patients and sample collection

A total of 135 gastric patients were recruited in this study, who were underwent resection of the primary tumor between June 2008 and March 2011 at Harbin Medical University. These fresh GC tissues and corresponding adjacent normal tissues were immediately snap-frozen in liquid nitrogen and stored at $-$ 80 ${}^{\circ}$ C for standby application. All tissue specimens were independently confirmed by two professional pathologists, and all enrolled patients did not obtain any treatment prior to surgery. After surgery, the histopathological investigations were performed, and the pathologic data were collected. The clinical information of all patients was obtained from medical records at Harbin Medical University. After surgery, all patients were followed up by special clinic reexamination, letters or telephones to calculate 5-year survival rate. All procedures of the present study were reviewed and approved by the Ethics Committee of Harbin Medical University (Number: 2007008). Written informed consent was collected from each participant.

2.2 Cell culture and transfection

The normal gastric epithelium cell line GES-1 and four GC cell lines (SGC-7901, HGC-27, MKN45 and BGC-823) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS). All cell cultures were performed in a humidified incubator with 5% CO ${}_{2}$ at 37 ${}^{\circ}$ C.

To regulate the expression of miR-652, cells were transfected with miR-652 mimic, miR-652 inhibitor or the corresponding negative controls (mimic NC and inhibitor NC), which were synthesized by the company of Gene-Pharma (Shanghai, China). MiR-652 mimic was used to enhance the activity of miR-652, while miR-652 inhibitor was used to inhibit the activity. Mimic NC and inhibitor NC was chemically modified nonsense single-stranded nucleic acids, which have no effect on miR-652 expression after transfected into cells. All the cells were seeded into 24-well plates 24 h before transfection, and the followed transfections were conducted using Lipofectamine 3000 reagent (Invitrogen, USA) according to the manufacturer’s protocols. A total of 48 h after transfection, cells were harvested for the follow-up experiment.

Figure 1.

Expression of miR-652 measured by qRT-PCR in GC tissues and cell lines. A. MiR-652 expression was upregulated in the GC tissues compared with the adjacent normal controls ( ${}^{***}P<$ 0.001). B. The expression of miR-652 was higher in the GC cell lines than that in the normal gastric cells ( ${}^{***}P<$ 0.001).

2.3 RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)

The total RNA was extracted from both GC tissues and cells using Trizol Reagent (Invitrogen, Carlsbad, CA, USA) based on the manufacturer’s protocol. Reverse transcription reactions were performed using the miScript Reverse Transcription Kit (QIAGEN, Germany), and real-time PCR was performed with SYBR green I Master Mix kit (Invitrogen, Carlsbad, CA, USA) using 7300 Real-Time PCR System (Applied Biosystems, USA). The comparative delta CT (2 ${}^{-\Delta\Delta\text{Ct}}$ ) method was used to determine the relative expression of miR-652, in which data were normalized to U6.

2.4 MTT assay

MTT assay was conducted to measure the cellular proliferation of stably transfected cells. A total of 48 h after transfection, the stably transfected cells were plated in a 96-well plate with the density of 5 $\times$ 10 ${}^{4}$ cells per well. At 0 h, 24 h, 48 h, 72 h after cell seeding, the cells were stained with 20 $\mu$ l of MTT (5 mg/ml; Sigma-Aldrich; Merck, Darmstadt, Germany) respectively at each time point. After incubation at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ for 4 h, 150 $\mu$ l of dimethyl sulfoxide (DMSO) (Sigma-Aldrich; Merck) was added into wells. Twenty minute later, the absorbance was measured at 490 nm using a microplate reader. Each assay was conducted three times, with five repeats respectively.

2.5 Transwell assay

Transwell migration and invasion assays were conducted to evaluate the migration and invasive ability of GC cells. Transwell inserts chambers with 8 $\mu$ m pore size polycarbonate membranes (Corning, USA) were used to separate the upper and the lower chambers. Generally, the upper chamber of Transwell device for cell migration and invasion were pre-coated with or without Matrigel (Corning, USA). GC cells (1 $\times$ 10 ${}^{5}$ cells/well) with different transfection were seeded into the upper chamber of the inserts in serum-free medium, and 300 $\mu$ l DMEM containing 10% FBS was added into the lower chambers. A light microscopy (magnification, $\times$ 100; Olympus Corporation, Tokyo, Japan) was used for the observation of the cells in the lower membrane, which were stained with 0.1% crystal violet, and the mean number of migrated or invaded cells was calculated in 5 random visual fields.

2.6 Luciferase reporter assay

PmiR-RB-REPORT ${}^{\text{TM}}$ luciferase vector containing the wide type of retinoid-related orphan receptor $\alpha$ (RORA) 3’-UTR (WT) or the mutant type (MUT) was supplied by a service provider (Guangzhou RiboBio Co. LTD, China). Before transfection, the BGC-823 cells were seeded into a 96-well plate and cultured for 24 h. Then the cells were cotransfected with 50 ng of either wild-type or mutant-type reporter vector and 200 ng of miR-652 mimic or inhibitor. Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) was used for the transfection. Relative luciferase activity was measured using the Dual-Luciferase Reporter System (Promega Corporation, Wisconsin, USA) according to the instructions of the manufacturer.

2.7 Statistical analysis

SPSS version 18.0 software (SPSS Inc., Chicago, IL) and GraphPad Prism 5.0 software (GraphPad Software, Inc., USA) were applied for the data analysis. Differences between two groups were compared by Student’s $t$ test, while the multiple groups comparisons were performed through one-way ANOVA analysis, followed by a Tukey’s multiple comparison test. Correlation between miR-652 expression and clinicopathological features was measured via the chi-square test. The overall survival of GC patients was assessed using Kaplan-Meier methods and log-rank test. Cox regression analysis was performed to further calculate the prognostic value of miR-652 in GC. A $P$ value less than 0.05 was regarded as statistically significant.

Figure 2.

Kaplan-Meier survival analysis for the GC patients based on the expression of miR-652. Patients with high miR-652 expression had shorter survival time than those with low miR-652 expression (log-rank $P<$ 0.001).

3. Results

3.1 Overexpression of miR-652 in GC tissues and cell lines

The miR-652 expression level was estimated in pairs of tumor tissues and corresponding adjacent normal tissues. The results suggested that miR-652 was mostly up-regulated in the GC tissues compared with matched normal tissues, and the differences reached a significant level ( $P<$ 0.001, Fig. 1A). The expression levels of miR-652 in GC cell lines SGC-7901, HGC-27, MKN45, BGC-823 and normal cell line GES-1 were also observed. The data indicated that the expression levels of miR-652 were significantly higher in GC cell lines than those in normal line (all $P<$ 0.001, Fig. 1B).

Figure 3.

Effects of miR-652 on cell proliferation in HGC-27 and BGC-823 cells. A. In the two cell lines, expression of miR-652 was significantly increased by miR-652 mimic transfection, but was decreased by miR-652 inhibitor transfection compared with the corresponding negative controls ( ${}^{**}P<$ 0.01 and ${}^{***}P<$ 0.001). B. Cell proliferation was promoted by overexpression of miR-652, but was suppressed by knockdown of miR-652 in both HGC-27 and BGC-823 cells ( ${}^{*}P<$ 0.05 and ${}^{**}P<$ 0.01).

Figure 4.

Effects of miR-652 on cell migration and invasion in HGC-27 and BGC-823 cells. A. The results of migration analysis for HGC-27 and BGC-823 cells. B. The results of invasion analysis for HGC-27 and BGC-823 cells. C and D. Overexpression of miR-652 by miR-652 mimic transfection could promote the cell migration and invasion, but the downregulated miR-652 expression could inhibit the cell migration and invasion ( ${}^{**}P<$ 0.01 and ${}^{***}P<$ 0.001).

Figure 5.

MiR-652 directly targets the conserved RORA 3’-UTR sequence. A. The putative miR-652 binding sequence in the RORA 3’-UTR. B. Analysis of the luciferase activity of the luciferase reporter plasmid containing either wild-type (WT) or mutant (MT) RORA 3’-UTR in BGC-823 cells ( ${}^{**}P<$ 0.01, compared with untreated cell).

Table 1

Association of miR-652 with the clinicopathological features of gastric cancer patients

Features	Total no.	MiR-652		$P$ values
	$N=$ 135	expression
		Low	High
		( $n=$ 63)	( $n=$ 72)
Age (Years)
$\leqslant$ 60	56	26	30	0.963
$>$ 60	79	37	42
Gender
Male	72	31	41	0.369
Female	63	32	31
Perineural invasion
Absence	80	37	43	0.907
Presence	55	26	29
Histological type
Differentiated	76	35	41	0.871
Undifferentiated	59	28	31
Tumor depth
T1–T2	87	39	48	0.564
T3–T4	48	24	24
TNM stage
I–II	75	43	32	0.005 ${}^{**}$
III–IV	60	20	40
Lymph node metastasis
No	72	40	32	0.027 ${}^{*}$
Yes	63	23	40

${}^{*}P<$ 0.05; ${}^{**}P<$ 0.01.

Table 2

Multivariate Cox regression analysis for miR-652 in gastric cancer patients

Variables	Multivariate analysis
	HR	95% CI	$P$ value
MiR-652	2.923	1.455–5.871	0.003 ${}^{**}$
Age	1.253	0.689–2.280	0.460
Gender	1.197	0.672–2.132	0.543
Perineural invasion	0.981	0.560–1.720	0.947
Histological type	1.348	0.739–2.457	0.330
Tumor depth	0.741	0.419–1.309	0.302
TNM stage	2.043	1.101–3.792	0.023 ${}^{*}$
Lymph node metastasis	1.617	0.888–2.944	0.116

${}^{*}P<$ 0.05; ${}^{**}P<$ 0.01.

3.2 Association of miR-652 expression with clinicopathological features of GC patients

The clinical data of the 135 patients were presented in Table 1. The mean expression level of miR-652 in GC tissues was defined as a cutoff to divide the patients into low ( $n=$ 63) and high miR-652 expression ( $n=$ 72) groups. We observed that the expression level of miR-652 was significantly associated with TNM stage ( $P=$ 0.005) and lymph node metastasis ( $P=$ 0.027). However, the miR-652 had no significant association with other clinicopathological features including age, gender, perineural invasion, histological type and tumor depth (all $P>$ 0.05, Table 1).

3.3 Prognostic value of miR-652 expression for patients with GC

The Kaplan-Meier survival curves and the log-rank test were performed to explore the correlation between miR-652 expression and patients’ survival. We found that patients with high miR-652 expression had significantly lower 5-year overall survival than those with low miR-652 expression (log-rank $P<$ 0.001, Fig. 2). The multivariate Cox analysis demonstrated that the miR-652 expression (HR $=$ 2.923, 95% CI $=$ 1.455–5.871, $P=$ 0.003) and TNM stage (HR $=$ 2.043, 95% CI $=$ 1.101–3.792, $P=$ 0.023) were independent prognostic indicators for overall survival in GC patients (Table 2).

3.4 Effects of miR-652 on cell proliferation in GC cells

Because the expression level of miR-652 was upregulated to a greater degree in HGC-27 and BGC-823 cell lines, the two cells were used for the subsequent studies. To further evaluate the functional effects of miR-652 on GC cell behaviors, cellular functional experiments were performed by transfecting miR-652 mimics, miR-652 inhibitor or corresponding negative controls into cells. As shown in Fig. 3A, miR-652 expression levels were significantly upregulated in the miR-652 mimic group compared with the mimic NC group, while were downregulated significantly in the miR-652 inhibitor group (all $P<$ 0.01). MTT assay was applied for the evaluation of the functional role of miR-652 on GC cell proliferation. The results suggested that the upregulation of miR-652 markedly promoted GC cell proliferation as compared with the negative control, while contrary results were obtained when downregulating miR-652 expression (all $P<$ 0.05, Fig. 3B).

3.5 Effects of miR-652 on cell migration and invasion in GC cells

The transwell assay was also conducted to calculate the involvement of miR-652 in GC cell migration and invasion. The data revealed that, in both HGC-27 and BGC-823 cells, the migrated and invasive cell numbers were increased significantly by miR-652 mimic transfection, while were decreased by miR-652 inhibitor transfection (all $P<$ 0.01, Fig. 4).

3.6 RORA was the target gene of miR-652

According to bioinformatics analysis by online software (TargetScan, miRNAMap and miRDB), RORA was identified to be a potential target of miR-652 (Fig. 5A). Furthermore, the luciferase reporter assay suggested that miR-652 mimic transfection attenuated the luciferase activity of RORA 3’-UTR, but it was not observed when the mutant RORA 3’-UTR expressed. On the contrary, the inhibition of miR-652 significantly promoted RORA 3’-UTR luciferase activity which was not detected under the mutant RORA 3’-UTR expression ( $P<$ 0.01, Fig. 5B).

4. Discussion

Although the incidence of GC shows decrease trend recently as a result of the people’s habits change and the smoking reduction, its survival rate is still modest [17, 18]. Up till now, the etiology and pathogenesis of GC have not been fully understood [19]. GC patients always have no characteristic manifestations in the early stage and can not accept treatment timely, which affects the prognosis of GC patients seriously [20]. Therefore, identifying new molecular markers that can be used as independent prognostic factors for GC is of great significance for the diagnosis and targeted treatment of GC [21]. A number of miRNAs have been reported to express aberrantly in different cancers, and be involved in many processes, such as cell proliferation, apoptosis, and stress response [22, 23, 24, 25]. Recently, a major study has suggested that miR-652 was overexpressed in GC patients than healthy controls [16]. But the function of miR-652 in tumorigenesis and progression of GC are still largely unknown.

In the present study, the expression level of miR-652 was examined in 135 GC patients, and the results revealed that the expression of miR-652 was upregulated significantly in GC tissues, which was further confirmed in GC cell lines. The results were supported by the previous results [16]. Consistently, overexpression of miR-652 has been reported in human prostate cancer cells, which might serve as a biomarker for aggressive prostate cancer [26]. Besides, the expression of miR-652-3p was also found to be significantly upregulated in non-small cell lung cancer (NSCLC) tissues, and showed significant association with lymph node metastasis, TNM stage and poor prognosis [27]. Sun et al. demonstrated that miR-652 was overexpressed in endometrial cancer, which was associated with poor survival rate and early recurrence [28]. All results suggested the carcinogenesis of miR-652 in different human cancers.

The Kaplan-Meier survival curves and log-rank test also demonstrated that patients with high miR-652 expression had significantly lower 5-year overall survival than those with low miR-652 expression. The multivariate Cox analysis further suggested the miR-652 expression and TNM stage to be independent prognostic indicators for overall survival in GC patients. Taken together, these results indicated that miR-652 might be a novel predictive marker for the poor prognosis of GC patients and might play an important role in the tumor progress.

Furthermore, the functional effects of miR-652 on GC cell behaviors were also detected, and overexpression of miR-652 was proved to significantly promote GC cell proliferation, migration and invasion. About the function effects of miR-652 on tumor cell progression, a number of studies have been reported in different human cancers. Nam et al. found that up-regulation of miR-652 enhanced prostate cancer cell growth, migration and invasion by promoting NED through decreased PP2A function [26]. Yang et al. indicated that overexpressing miR-652 resulted in decreased expression of Lgl1 protein, and can promote cell proliferation, migration, invasion and inhibit cell apoptosis [27]. Sun et al. revealed that miR-652 might function as an oncogene in endometrial cancer, and overexpression of miR-652 would promote the tumor progression [28]. All evidence suggested the crucial role of miR-652 in tumor progression.

RORA is a nuclear receptor which belongs to the ROR sub-family [29]. In the present study, RORA was predicted to be a target gene of miR-652 in GC cells according to bioinformatics analysis, which has been widely reported to be involved in cancer progression, including GC [30, 31, 32]. Furthermore, the luciferase reporter assay was performed to confirm RORA to be the target gene of miR-652 in GC. RORA has been reported to be downregulated in human GC tissues, as well as GC cell lines [32]. And the reduction of RORA was reported to be associated with tumor progression and poor prognosis of GC [32]. Combined with the previous evidence, we concluded that miR-652 functions as an oncogene in GC and promotes tumor progression via targeting RORA.

In conclusion, we confirmed that miR-652 expression was increased in GC tissues, as well as GC cell lines. To the best of our knowledge, this is the first study exploring the correlation between altered miR-652 and prognosis in GC patients, and miR-652 was demonstrated to be correlated with clinical outcomes. Moreover, miR-652 was able to promote the tumor progression of GC cells via targeting RORA. Therefore, the present study highlighted that miR-652 might be a useful therapeutic target to improve the survival of GC patients.

Footnotes

Conflict of interest

The authors report no conflicts of interest in this work.

References

Quan

Ning

Wang

and Zhu

, Prognostic value of upregulation of myristoylated alanine-rich c-kinase substrate in gastric cancer, Med Sci Monit 25 (2019), 279–287.

Guo

Deng

Wang

Xia

Shan

Liang

Yao

and Jin

, GAS5 inhibits gastric cancer cell proliferation partly by modulating CDK6, Oncol Res Treat 38 (2015), 362–366.

Dong

and Liu

, Expression and significance of miR-24 and miR-101 in patients with advanced gastric cancer, Oncol Lett 16 (2018), 5769–5774.

Zhu

Shi

Zhang

and Li

, KLK6 promotes growth, migration, and invasion of gastric cancer cells, J Gastric Cancer 18 (2018), 356–367.

Zhu

Wang

Luo

Liu

and Zhang

, Development and validation of a prognostic signature for preoperative prediction of overall survival in gastric cancer patients, Onco Targets Ther 11 (2018), 8711–8722.

Wan

Song

and Fang

, Serum miR-658 induces metastasis of gastric cancer by activating PAX3-MET pathway: a population-based study, Cancer Biomark 22 (2018), 111–118.

Manne

R.K.

Agrawal

Bargale

Patel

Paul

Gupta

N.A.

Rapole

Seshadri

Subramanyam

Shetty

and Santra

M.K.

, A MicroRNA/Ubiquitin ligase feedback loop regulates slug-mediated invasion in breast cancer, Neoplasia 19 (2017), 483–495.

Cui

Wang

and Wang

, MiR-141-3p functions as a tumor suppressor through directly targeting ZFR in non-small cell lung cancer, Biochem Biophys Res Commun (2019).

Zong

Liu

Zhou

and Yue

, E2F7, EREG, miR-451a and miR-106b-5p are associated with the cervical cancer development, Arch Gynecol Obstet (2019).

10.

Yachi

Tsuda

Kohsaka

Wang

Oda

Tanikawa

Ohba

and Tanaka

, miR-23a promotes invasion of glioblastoma via HOXD10-regulated glial-mesenchymal transition, Signal Transduct Target Ther 3 (2018), 33.

11.

Wang

Huang

and Zhang

, MiR-29b suppresses proliferation and mobility by targeting SOX12 and DNMT3b in pancreatic cancer, Anticancer Drugs (2018).

12.

Zhang

Deng

Sun

Ning

Fan

Wang

Zhang

Zhou

Yang

Ying

and Ba

, MiR-181a, a new regulator of TGF-beta signaling, can promote cell migration and proliferation in gastric cancer, Invest New Drugs (2019).

13.

Guo

Zhao

Yang

Huang

and Zhang

, MicroRNA-371a-3p promotes progression of gastric cancer by targeting TOB1, Cancer Lett 443 (2019), 179–188.

14.

Zhang

Xuan

Wang

Chen

Wang

Sun

and Xu

, Novel role of miR-133a-3p in repressing gastric cancer growth and metastasis via blocking autophagy-mediated glutaminolysis, J Exp Clin Cancer Res 37 (2018), 320.

15.

Tian

Wang

Z.Y.

Hao

and Zhang

X.Y.

, miR-505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1, J Cell Biochem (2018).

16.

Shin

V.Y.

E.K.

Chan

V.W.

Kwong

and Chu

K.M.

, A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer, Mol Cancer 14 (2015), 202.

17.

Allemani

Weir

H.K.

Carreira

Harewood

Spika

Wang

X.S.

Bannon

Ahn

J.V.

Johnson

C.J.

Bonaventure

Marcos-Gragera

Stiller

Azevedo e Silva

Chen

W.Q.

Ogunbiyi

O.J.

Rachet

Soeberg

M.J.

You

Matsuda

Bielska-Lasota

Storm

Tucker

T.C.

and Coleman

M.P.

, Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet 385 (2015), 977–1010.

18.

Ferlay

Soerjomataram

Dikshit

Eser

Mathers

Rebelo

Parkin

D.M.

Forman

and Bray

, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer 136 (2015), E359–386.

19.

Tas

Karabulut

Erturk

and Duranyildiz

, Clinical significance of serum caveolin-1 levels in gastric cancer patients, Exp Oncol 40 (2018), 323–327.

20.

Wang

and Qin

, Prognostic and clinicopathological significance of long noncoding RNA CTD-2510F5.4 in gastric cancer, Gastric Cancer (2018).

21.

Ueta

Otowa

Kakeji

and Hirashima

, PROX1 is associated with cancer progression and prognosis in gastric cancer, Anticancer Res 38 (2018), 6139–6145.

22.

Hiroki

Akahira

Suzuki

Nagase

Ito

Suzuki

Sasano

and Yaegashi

, Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas, Cancer Sci 101 (2010), 241–249.

23.

Z.D.

Xin

H.N.

Yang

Z.C.

Wang

W.J.

Dong

J.J.

Jin

L.Y.

and Li

F.N.

, miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer, J Cell Physiol (2019).

24.

Xie

Liu

Zhang

Yao

and Yang

, MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway, J Exp Clin Cancer Res 38 (2019), 7.

25.

Xin

Wang

and Liu

, miR-196a-5p promotes metastasis of colorectal cancer via targeting IkappaBalpha, BMC Cancer 19 (2019), 30.

26.

Nam

R.K.

Benatar

Amemiya

Wallis

C.J.D.

Romero

J.M.

Tsagaris

Sherman

Sugar

and Seth

, MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells, Oncotarget 9 (2018), 19159–19176.

27.

Yang

Zhou

Luo

Shi

Sun

Zhou

Chen

and He

, MiR-652-3p is upregulated in non-small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1, Oncotarget 7 (2016), 16703–16715.

28.

Sun

Dongol

Qiu

Sun

Zhang

Yang

Zhang

and Kong

, MiR-652 promotes tumor proliferation and metastasis by targeting RORA in endometrial cancer, Mol Cancer Res 16 (2018), 1927–1939.

29.

Solt

L.A.

and Burris

T.P.

, Action of RORs and their ligands in (patho) physiology, Trends Endocrinol Metab 23 (2012), 619–627.

30.

R.D.

Qiu

C.H.

Chen

H.A.

Zhang

Z.G.

and Lu

M.Q.

, Retinoic acid receptor-related receptor alpha (RORalpha) is a prognostic marker for hepatocellular carcinoma, Tumour Biol 35 (2014), 7603–7610.

31.

and Xu

, RORalpha, a potential tumor suppressor and therapeutic target of breast cancer, Int J Mol Sci 13 (2012), 15755–15766.

32.

Wang

Xiong

Wang

Zhu

and Zhu

, Nuclear receptor retinoid-related orphan receptor alpha promotes apoptosis but is reduced in human gastric cancer, Oncotarget 8 (2017), 11105–11113.

MiR-652 serves as a prognostic biomarker in gastric cancer and promotes tumor proliferation,migration,and invasion via targeting RORA

Abstract

PURPOSE:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and sample collection

2.2 Cell culture and transfection

2.4 MTT assay

2.5 Transwell assay

2.6 Luciferase reporter assay

2.7 Statistical analysis

3.1 Overexpression of miR-652 in GC tissues and cell lines

3.3 Prognostic value of miR-652 expression for patients with GC

3.4 Effects of miR-652 on cell proliferation in GC cells

3.5 Effects of miR-652 on cell migration and invasion in GC cells

3.6 RORA was the target gene of miR-652

4. Discussion

Footnotes

Conflict of interest

References